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Acute Q fever is a zoonotic disease caused by the obligate intracellular bacterium Coxiella burnetii and can
manifest as a flu-like illness, pneumonia, or hepatitis. A need exists in Q fever research for animal models
mimicking both the typical route of infection (inhalation) and the clinical illness seen in human cases of Q
fever. A guinea pig aerosol challenge model was developed using C. burnetii Nine Mile phase I (RSA 493),
administered using a specialized chamber designed to deliver droplet nuclei directly to the alveolar spaces.
Guinea pigs were given 101 to 106 organisms and evaluated for 28 days postinfection. Clinical signs included
fever, weight loss, respiratory difficulty, and death, with the degree and duration of response corresponding to
the dose of organism delivered. Histopathologic evaluation of the lungs of animals infected with a high dose
showed coalescing panleukocytic bronchointerstitial pneumonia at 7 days postinfection that resolved to mul-
tifocal lymphohistiocytic interstitial pneumonia by 28 days. Guinea pigs receiving a killed whole-cell vaccine
prior to challenge with the highest dose of C. burnetii were protected against lethal infection and did not develop
fever. Clinical signs and pathological changes noted for these guinea pigs were comparable to those seen in
human acute Q fever, making this an accurate and valuable animal model of human disease.
Q fever is a disease of worldwide importance for both hu-
mans and other animals and is caused by the obligately intra-
cellular bacterium Coxiella burnetii. Sheep, goats, and cattle are
the primary reservoirs of the organism and can shed it in milk,
urine, feces, and birth products (2). Thus, occupational expo-
sure of persons in contact with these animals, such as abattoir
workers, farmers, and veterinarians, is associated with a higher
risk of contracting Q fever. C. burnetii has also been found in
numerous other mammals, birds (51, 55), reptiles (21, 52, 61),
and arthropods (5, 9, 49). Humans are infected primarily
through inhalation, and as few as 10 organisms are known to
cause disease (4). Ingestion of contaminated dairy products
(18, 24, 54) or bites from infected ticks (9, 10, 44) may also lead
to infection.
C. burnetii has a high degree of resistance to physical and
chemical agents (38, 46) and can withstand desiccation and
remain infectious in contaminated soils for years (53). Due to
the highly infectious nature of C. burnetii and its hardiness
under adverse environmental conditions, the organism is con-
sidered a category B agent by the Centers for Disease Control
and Prevention and has been included in the list of weapons of
mass destruction likely to be used in bioterrorism and biolog-
ical warfare (13, 23). Weaponization and mass production of
this organism have already been accomplished (43, 48), rein-
forcing the need for a safe, efficacious vaccine that could be
used to protect populations at risk following a deliberate or
natural outbreak.
Human Q fever can present as either acute or chronic in-
fection. Acute Q fever generally presents as a flu-like illness
with severe periorbital headache, high fever, malaise, myalgia,
rare nonproductive cough, and weight loss (29, 33). This illness
can progress to Q fever pneumonia, characterized by gross
lung consolidation and an interstitial pneumonia with bron-
chial and alveolar exudates and inflammatory infiltrates con-
sisting primarily of lymphocytes and macrophages (29, 31, 37).
Acute Q fever patients may also develop hepatitis (8), alone or
in combination with the respiratory illness (30). Chronic Q
fever often presents as endocarditis (14) and/or hepatitis and
has been diagnosed occasionally in osteomyelitis cases (36, 41).
An association has also been made between a chronic fatigue-
like syndrome and Q fever (27, 40, 58, 60).
Animal models commonly used in the study of Q fever
include mice, guinea pigs, nonhuman primates, and livestock.
Mice are utilized most often due to the many relevant genetic
and immunologic tools available, and differences in strain sus-
ceptibilities have been noted (47). Immunocompetent mice
require a large number of organisms to develop clinical signs of
illness, and splenomegaly is recognized as the primary indica-
tor of disease (12), in contrast to fever as the primary indicator
in guinea pigs (17), which can develop clinical illness after
intraperitoneal (i.p.) infection with as few as 10 organisms (35).
It has been shown that guinea pigs inoculated i.p. exhibit dose-
dependent fever and have more pathologic changes associated
with the liver, whereas those infected intranasally have greater
involvement of the lungs (22). Mice are used essentially as a
clearance model, relying on the mouse’s ability to control in-
fection after uptake of the organism. Guinea pigs can be used
as a model of clinical disease and therefore would be more
relevant for testing vaccines or antibiotic regimens for human
use.
For this study, guinea pigs were infected with C. burnetii
across a 5-log range of challenge doses through inhalation of
small-particle aerosols. These exposures resulted in a dose-
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responsive relationship to clinical and pathologic changes. The
disease produced in the guinea pig aerosol challenge model
closely mimics human acute Q fever and Q fever pneumonia.
The experiments presented here fill in gaps in the current
knowledge concerning the consequences of aerosol infection
with C. burnetii by using a physiologically relevant model, in-
cluding the dose response to infection, kinetics of extrapulmo-
nary dissemination, and pathologic and histopathologic changes
resulting from aerosol exposure.
MATERIALS AND METHODS
Animals. Six- to eight-week-old female outbred Hartley guinea pigs obtained
from Charles River Laboratories (Wilmington, MA) were housed in microiso-
lator caging in a biosafety level 3 facility with a 12-h–12-h light-dark cycle and
were given Harlan Teklad (Madison, WI) guinea pig diet and water ad libitum.
Guinea pigs were acclimated to the facility and assessment procedures for 1 week
prior to infection to reduce stress-related abnormalities. A modified Karnofsky
performance status scoring system was used to determine if humane euthanasia
was necessary after infection. All animal experimentation was reviewed and
approved by the Texas A&M University Laboratory Animal Care Committee
and was performed in an AAALAC-approved facility in accordance with uni-
versity and federal regulations.
Purification of C. burnetii. C. burnetii Nine Mile (RSA493), an isolate origi-
nating from a tick pool, was harvested from infected L929 mouse fibroblast cells
by pooling infected cells and centrifuging them at 1,000  g for 5 min. The
supernatant was then centrifuged at 15,000 g for 30 min to collect the naturally
released bacteria, and the resulting pellet was resuspended in 0.25 M sucrose
phosphate (SP) buffer (53.9 mM Na2HPO4, 12.8 mM KH2PO4, 72.6 mM NaCl,
250 mM sucrose). Double-distilled H2O was added to the original pellet. This
suspension was passed through an 18-gauge canula, lysis was monitored by visual
inspection, and an equal volume of 0.25 M SP was added when the majority of
the cells were lysed. Benzonase, a nonspecific nuclease (Novagen, Madison, WI),
was added to the lysed cell suspension for 5 min at room temperature. Cells were
resuspended several times with a pipette before pelleting of host cells by cen-
trifugation at 1,000  g for 5 min. The supernatant was combined with the
naturally released bacteria, and the combination was pelleted by centrifugation
at 14,000  g for 30 min. The supernatant was discarded, and the pellet was
resuspended in SP. Host cell debris was pelleted by centrifugation at 1,000  g
for 5 min, and the pellet was discarded. Bacteria in the supernatant were pelleted
by centrifugation at 14,000  g for 30 min, the pellet was resuspended in SP, and
the purity of the bacterial pellet was ascertained by examination of heat-fixed
cells with Gimenez stain.
Quantification of C. burnetii inoculum. C. burnetii Nine Mile (RSA493) was
quantified by three methods. The optical density (OD) was used to determine the
number of particles in the stock solution, as previously described (39). Particle
counts were performed using a Live/Dead BacLight bacterial viability kit (Mo-
lecular Probes, Eugene, OR) according to the manufacturer’s instructions. Prim-
ers amplifying the com-1 gene were used to enumerate C. burnetii genome copies
by real-time PCR, as previously described (7). A dose of 2  106 organisms
determined by OD measurement corresponded to 1.7  106 organisms by par-
ticle counting with 95% viability and to 1.1  106 genome equivalents by real-
time PCR. Infectious doses described in this paper are those enumerated by OD
measurement.
Infection. Guinea pigs were exposed to phase I C. burnetii Nine Mile
(RSA493) in phosphate-buffered saline (PBS) or to PBS alone (negative con-
trol), using a chamber specially designed to deliver droplet nuclei directly to the
alveolar spaces (College of Engineering Shops, University of Wisconsin, Madi-
son, WI) (34, 59). This chamber allows the infection of multiple guinea pigs
simultaneously, ensuring uniform infection within each group.
Experimental design. (i) Experiment 1. Fourteen guinea pigs were exposed to
2  106 C. burnetii organisms, and two negative control animals were sham
infected with sterile PBS. Clinical assessments of disease progression were per-
formed daily for 28 days, including assessments of behavior, weight, and rectal
temperature, thoracic auscultation, and abdominal palpation. Temperatures of
39.5°C were defined as fever. Euthanasia by a ketamine-xylazine overdose
followed by exsanguination was performed at 7, 14, or 28 days postinfection (p.i.)
or as indicated by the Karnofsky score. Spleens and livers were weighed at
necropsy, and hearts, lungs (perfused), livers, spleens, and kidneys were collected
and fixed in formalin for evaluation by histopathology and immunohistochemis-
try.
(ii) Experiment 2. Three guinea pigs per dose were exposed to 2  106, 2 
105, 2  104, 2  103, 2  102, or 2  101 C. burnetii organisms, based on optical
density-determined bacterial number correlation; three negative control animals
were sham infected with PBS. Three vaccinated guinea pigs (see below) were
infected with 2  106 C. burnetii organisms. Clinical and pathologic assess-
ments were performed as described for experiment 1.
Guinea pigs infected with 2  106 C. burnetii organisms from experiment 2
were combined with those from experiment 1 to develop a survival curve.
Vaccination. Guinea pigs were given subcutaneous injections of 100 g for-
malin-killed phase I Nine Mile C. burnetii in incomplete Freund’s adjuvant twice,
with 2-week intervals between vaccinations and between the final vaccination and
infection. Blood was collected from all animals prior to infection for serological
confirmation of vaccination efficacy.
Histopathology and immunohistochemistry. Tissues collected at necropsy
were fixed in 10% buffered formalin for a minimum of 48 h. Tissues were
sectioned and embedded in paraffin, cut to a thickness of 5 m, allowed to
adhere to slides, and stained routinely with hematoxylin and eosin. Unstained
slides were prepared for immunohistochemical staining. A Vectastain ABC kit
and a Vector NovaRED substrate kit (Vector Laboratories, Burlingame, CA)
were used with rabbit anti-Nine Mile C. burnetii serum generated in our labo-
ratory for immunostaining of C. burnetii in tissue sections (3); slides were coun-
terstained with hematoxylin. All slides were evaluated in a blinded fashion.
Serology. Serum samples collected at necropsy were tested by enzyme-linked
immunosorbent assay in 96-well U-shaped polystyrene plates (Fisher Scientific,
Houston, TX) coated with 50 l of 0.5-g/ml phase I Nine Mile C. burnetii
antigen (formalin-killed whole cells) diluted in 0.1 M sodium carbonate buffer
(pH 9.6) per well. After 24 h of incubation at 4°C, plates were emptied and
blocked for 1 h at 37°C in 1% bovine serum albumin–PBS–Tween 20 (BSA-
PBST). Serum was heat inactivated at 56°C for 30 min, dilutions of 1:400 to
1:102,400 were prepared in 1% BSA-PBST, and 50 l of sample and 50 l of 1%
BSA-PBST were added to each well and incubated at room temperature for 2 h.
Plates were washed four times with distilled H2O and then incubated with 100 l
of goat anti-guinea pig immunoglobulin G (Bethyl Laboratories, Montgomery,
TX) diluted 1:1,000 for 2 h at room temperature before being washed again four
times with distilled H2O. One hundred microliters of substrate (Sigma Fast
o-phenylenediamine dihydrochloride; Sigma-Aldrich, St. Louis, MO) was incu-
bated in each well for 5 to 10 min in the dark at room temperature, and the
reaction was stopped with 100 l 1 M H2SO4 per well. Plates were read at 490
nm in a Dynatech MR5000 microplate reader (Dynatech Laboratories, Chantilly,
VA). Uninfected guinea pig serum was used as a negative control.
Statistical analysis. Results were expressed as means  standard errors and
were compared using Student’s t test. Differences were considered significant at
P values of 0.05.
RESULTS
Clinical signs of infection with C. burnetii delivered via
small-particle aerosol. Guinea pigs infected with 2  106 C.
burnetii organisms developed fever (39.5°C) by day 5 p.i. The
temperature peaked at 40.8°C on day 7 p.i. and returned to
normal by day 13 p.i. in surviving animals. Thereafter, the
temperature remained within normal parameters for 28 days.
Animals infected at all lower doses showed initial fever re-
sponses on later days. A dose-dependent relationship was
noted for both the onset and degree of fever (Table 1).
All guinea pigs infected with 2  104 to 2  106 C. burnetii
organisms experienced inappetence and lethargy correspond-
ing with the onset of fever. Weight loss began as early as day
4 p.i. in animals infected with 2  106 organisms, was statisti-
cally significant (P  0.01) by day 5, and continued until death
or until days 11 to 13 in surviving guinea pigs. Mild to moder-
ate clinical dehydration was apparent by day 6 or 7 p.i. in these
animals and only resolved with the alleviation of fever. Guinea
pigs given 2  101 to 2  103 organisms had no significant
weight loss or dehydration associated with disease.
Increased respiratory rates, sounds, and efforts were de-
tected starting at days 5 and 6 p.i. for the infection group
receiving 2 106 cells. Consolidation and crackles (rales) were
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noted on auscultation, with uniform distribution between the
right and left sides. Upper respiratory obstruction was mini-
mal. Paling and faint cyanosis of the muzzle were evident.
Nasal discharge, though present, was rapidly cleaned away by
the guinea pigs and therefore only noted sporadically through-
out the main course of infection.
A 70.6% total mortality rate (12/17 animals from experi-
ments 1 and 2) was noted for nonvaccinated guinea pigs in-
fected with 2  106 C. burnetii organisms, with spontaneous
death (75%) or humane euthanasia (25%) occurring from days
7 to 10 p.i. (Fig. 1); no animals died after 10 days postinfection.
Groups infected at all lower doses had no fatalities, and the
50% lethal dose was calculated to be 2  105.7 by the method
of Reed and Muench (42).
Vaccination prior to infection conferred complete protec-
tion against the development of fever, respiratory abnormali-
ties, and death. The lack of clinical signs of illness was com-
parable between the vaccinated, infected animals and those
that were sham infected with PBS (Table 1).
Pathologic changes in guinea pigs infected with C. burnetii.
At 7 days p.i., guinea pigs exposed to 2  106 C. burnetii
organisms displayed complete gross consolidation of cranial
lung lobes and partial consolidation of caudal lobes at nec-
ropsy. Several multifocal, pinpoint, white foci were noted
throughout the lungs in both the cranial and caudal lobes. The
liver was mottled and pale, with a yellowish discoloration.
These animals also had a noticeable lack of abdominal fat. By
14 days p.i., lung consolidation had largely resolved in surviving
guinea pigs. The liver appeared as described for 7 days p.i., and
there was still a lack of abdominal fat. Moderate, transient
splenomegaly (P  0.01) was also noted (data not shown). A
calculation of relative spleen-to-body-weight ratios also
showed statistical significance (P  0.05) at 7 days p.i., al-
though this was likely an artifact due to the rapid, severe
weight loss of the animals at that time. Multifocal, pinpoint-
to-4-mm, white foci were present in the lungs at 28 days p.i.
The liver continued to appear somewhat mottled, but colora-
tion returned to normal, and pinpoint-to-2-mm, white-to-tan
foci were present in some animals.
Histopathologic evaluation (Fig. 2) at 7 days p.i. revealed a
coalescing, panleukocytic, bronchointerstitial pneumonia (Fig.
2B, panels 1 to 3). Lungs were hyperemic, and alveolar walls
were thickened due to cellular infiltration consisting primarily
of neutrophils and lymphocytes, although all inflammatory cell
types were present to some extent. The amount of bronchus-
associated lymphoid tissue was increased (Fig. 2B, panel 1,
arrows). Extensive bronchial and alveolar exudates were noted
throughout the sections. Purulent bronchial exudates (Fig. 2B,
panel 2) were prominent, with degeneration and sloughing of
the bronchial epithelial lining. Alveolar exudates (Fig. 2B,
panel 3) were a deep pink, indicating a high protein content.
By 28 days p.i., lung changes resolved to multifocal, lympho-
histiocytic, interstitial pneumonia with granuloma formation
(Fig. 2C, panels 1 to 3). Granulomas (Fig. 2C, panel 2, arrows,
and panel 3) varied in size and distribution and consisted
primarily of aggregates of macrophages surrounded by lym-
phocytes.
Severe, diffuse hepatic lipid accumulation (Fig. 3A) was
present at 7 days p.i. Centrilobular hepatocellular degenera-
tion and vacuolization were noted in the liver, along with
periportal lymphocyte infiltration and multiple small granulo-
mas at 14 and 28 days p.i. (Fig. 3B). One guinea pig evaluated
at 14 days p.i. was noted to have extensive focal necrosis and
mineralization in a section of the liver. Disruption of normal
splenic architecture (Fig. 3C) was most apparent at 14 days p.i.,
corresponding to the gross splenomegaly observed at necropsy,
FIG. 1. Percent survival after infection with 2  106 C. burnetii
cells. Inoculation with 2  106 C. burnetii organisms resulted in mor-
tality in 12/17 guinea pigs within the first 10 days of infection, with no
deaths occurring thereafter.
TABLE 1. Response to infection with C. burnetii
Infectious dose
(no. of organisms)
No. of animals
with fever/total
no. of animals
Earliest onset
of fever
(day)b
Avg duration
of fever
(days)b
Highest
temp
(°C)
No. of
deaths/total
no. of animals
No. of
seroconversions/
total no. of
animals
Enzyme-linked
immunosorbent
assay titer
(range) at
28 days p.i.
PBS control 0/3 NA NA 39.3 0/3 0/3 0
2  101 2/3 14 1 39.6 0/3 3/3 100
2  102 3/3 14 1.67 39.9 0/3 3/3 400–800
2  103 3/3 10 2.67 39.9 0/3 3/3 1,600–3,200
2  104 3/3 6 4 40.6 0/3 3/3 3,200–51,200
2  105 3/3 6 6 40.9 0/3 3/3 51,200–102,400
2  106 3/3 5 5a 40.8 2/3 1/3a 25,600
2  106 (given to
vaccinated animals)
0/3 NA NA 39.4 0/3 3/3 25,600–102,400
a Number may be skewed due to deaths.
b NA, not available.
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and granulomas were present in the spleen at both 14 and 28
days p.i. (Fig. 3D). Vascular thrombi were noted in several
tissues at 28 days p.i. Mineralization of kidney tubules was
occasionally noted. Although some guinea pigs exhibited a
mild lymphocytic myocarditis or pericarditis, there was no ev-
idence of valvular endocarditis at any time postinfection.
Animals infected at lower doses and necropsied at 28 days
p.i. displayed progressively less severe signs of pneumonia and
hepatic degeneration (Table 2). No significant pathologic
changes were noted in negative control and vaccinated guinea
pigs (Fig. 2A, panels 1 to 3, and D, panels 1 to 3).
Immunohistochemistry confirmed the presence of C. burnetii
organisms in infected animals in the lungs, liver, and spleen
(Table 2). Bacteria were most prominent in macrophages but
were also noted in other cell types, primarily pneumocytes in
the lungs.
Serologic response to infection. Infected guinea pigs in all
dose groups seroconverted by the time of euthanasia, with the
exception of animals necropsied at 7 days p.i. The extent of
seroconversion was dose dependent (Table 1). No PBS control
animals seroconverted.
DISCUSSION
A need exists in Coxiella research for an animal model that
simulates both the natural route of infection and common
clinical presentations associated with human acute Q fever
infection. Such a physiologically relevant model would be valu-
able not only for testing vaccines and therapeutic agents but
also for evaluating the comparative virulence of different C.
burnetii isolates. Moos and Hackstadt showed a difference in
virulence between two isolates, Nine Mile and Priscilla, in an
i.p. challenge guinea pig model (35), and Kazar et al. also
demonstrated a lower virulence of Priscilla than of the Nine
Mile and S isolates (20). No histologic changes were described
by Stein et al. for Q212-infected mice compared to multiple
pathological changes in Nine Mile-infected animals (50). The
guinea pig aerosol challenge model described here is able to
FIG. 2. Q fever pneumonia. Hematoxylin- and eosin-stained lung tissues from guinea pigs infected with 2  106 C. burnetii organisms at 7 and
28 days p.i. were compared to those from PBS-treated controls (A1 to A3). Panleukocytic bronchointerstitial pneumonia with bronchial and
alveolar exudates was seen at 7 days p.i. (B1 to B3) (arrows indicate bronchus-associated lymphoid tissue). Granulomatous pneumonia was present
at 28 days p.i. (C1 to C3) (arrows indicate pulmonary granulomas). No significant pathological change was noted in guinea pigs vaccinated prior
to infection (D1 to D3).
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discern differences in disease manifestation within and be-
tween the six C. burnetii genomic groups (unpublished data).
This model would also be useful for examining the kinetics of
extrapulmonary distribution of C. burnetii, especially in whole
blood and serum, in the very early stages of infection for the
purpose of improving diagnostic tests for use in humans fol-
lowing a suspected exposure or outbreak.
The dose-responsive nature of infection in the guinea pig
aerosol challenge model was expected and consistent within
each group. This clinical dose-response effect has been noted
previously for humans (4, 32) and cynomolgus macaques (15).
Guinea pigs receiving small numbers of organisms took longer
to develop a low-grade fever for a brief period of time, in some
cases as little as 1 day. Conversely, guinea pigs receiving larger
numbers of organisms developed a high fever which persisted
longer than the case for the former group. Fatalities noted for
animals exposed to 2  106 C. burnetii organisms were likely
due to severe respiratory insufficiency. Guinea pigs receiving 2
 103 to 2  105 organisms, though also experiencing respi-
ratory difficulty and showing histologic evidence of pneumonia,
were able to overcome the illness. A 50% lethal dose of 2 
105.7 C. burnetii organisms was determined for this model. The
aerosol challenge mouse model described by Stein et al. re-
quired 108 C. burnetii organisms before any pathological
changes were noted at early times postinfection, suggesting
that a large amount of the organism must be present in aero-
sols for the development of Q fever (50), whereas the guinea
pig model displays clinical and pathological evidence of Q
fever over a wider and lower range of doses at more times
postinfection, and the consistent development of fever, easily
measurable antemortem, makes the guinea pig a much more
sensitive model. As opposed to reports using high doses of C.
burnetii for infection via inhalation in guinea pigs (20), this
study showed that guinea pigs exposed to as few as 2  101
organisms are able to develop acute Q fever, as is the case for
humans.
The histologic characteristics of the pneumonia which de-
FIG. 3. Q fever hepatopathies and splenic changes. Hematoxylin- and eosin-stained liver and spleen sections show (A) hepatic lipidosis at 7 days
p.i., (B) a hepatic granuloma at 14 days p.i., (C) disruption of normal splenic architecture at 14 days p.i., and (D) splenic granulomas at 14 days
p.i. in guinea pigs infected with 2  106 C. burnetii organisms.
TABLE 2. Histopathology a and immunohistochemistry b in tissues
of guinea pigs infected with C. burnetii
Infectious dose
(no. of organisms)
Score
Lungs Livers Spleens
H I H I H I
PBS control 0  0  0 
2  101 1  0  0 
2  102 1  1  0 
2  103 2  1  1 
2  104 3  2  1 
2  105 3  2  1 
2  106 3  3  2 
2  106 (given to
vaccinated animals)
0  0  0 
a The severity of histopathology (H) is based on the amount of architectural
change, cellular infiltration, and the presence or absence of necrosis, as follows:
0, none; 1, mild; 2, mild to moderate; 3, moderate; 4, moderate to severe;
5, severe.
b For immunohistochemistry (I), the following score system was used: , no
organisms present in the tissue section; , the presence of the organism is rare
and focal; , few organisms are multifocally present; , many organisms
are diffusely present; , an abundance of organisms are diffusely present.
Scores are the averages for sections evaluated for three guinea pigs per group at
28 days p.i. The evaluation of tissue sections was performed in a blinded fashion.
VOL. 74, 2006 GUINEA PIG AEROSOL CHALLENGE MODEL OF Q FEVER 6089
 o
n
 Septem
ber 21, 2018 by guest
http://iai.asm
.org/
D
ow
nloaded from
 
veloped in the guinea pigs in this study corresponded to those
seen for human Q fever pneumonia (29, 31, 37). The change
from the panleukocytic bronchointerstitial pneumonia seen at
7 days p.i. in animals infected with 2  106 organisms to a
lymphohistiocytic or granulomatous pneumonia by 28 days p.i.
showed resolution of the pneumonia and recovery, but it is
unknown at this time how long the pulmonary (and hepatic)
granulomas may persist postinfection. Should these granulo-
mas remain and contain viable organisms, it is possible that
they could be sites of persistent or latent infection, like the
placenta (41), bone marrow (28), and liver (16) in humans.
For many animals, hepatic lipidosis has been associated with
periods of anorexia, similar to that seen for guinea pigs in-
fected at higher doses in this study, leading to an excess of
triglycerides in the liver, intrahepatic cholestasis, and liver fail-
ure. Guinea pigs are known to develop fatty livers as a result of
reduced carbohydrate intake and mobilization of fat as an
energy source, most often associated with fasting metabolic
pregnancy toxemia (45). The hepatic steatosis seen at 7 days
p.i. in our guinea pigs infected via aerosol with 2  106 C.
burnetii organisms has been reported previously for i.p. inoc-
ulated guinea pigs at 3 to 4 days p.i. Increases in triglycerides,
unesterified fatty acids, and cholesterol have been noted dur-
ing early Q fever infection in these animals, and it is thought
that the development of a fatty liver is due to a failure of the
liver to export these lipids after their mobilization to the liver
(6). An association has also been suggested between fatty liver
development and changes in the plasma membrane peptide
composition which alter lipid transport (25). This steatohepa-
titis resolved after the main course of infection when the ani-
mals resumed eating and was no longer apparent at 14 and 28
days p.i., when centrilobular hepatocellular degeneration and
vacuolization were noted. Centrilobular hepatic degeneration
is a zonal change centered about the central vein (hepatic
venule) and is generally caused by low oxygen tension or a high
concentration of enzymes associated with bioactivation of toxic
compounds. Low oxygen tension, in this case, could be caused
by the severe respiratory insufficiency and resulting hypoxia
displayed by guinea pigs infected with high doses of C. burnetii.
There is currently no licensed vaccine against Q fever in the
United States, although a killed whole-cell vaccine (QVax;
CLS Ltd.) available in Australia has been shown to be highly
successful in the prevention of clinical disease in humans (19)
as well as in rodent (56) and nonhuman primate (57) models.
However, this vaccine can cause severe necrotic lesions or
granuloma development at the injection site in humans previ-
ously exposed to C. burnetii (11, 26) and thus requires skin
testing prior to vaccination. A new, efficacious vaccine without
such deleterious side effects is needed, and appropriate animal
models of human Q fever will be required to evaluate the
safety and efficacy of new vaccine candidates. Guinea pigs in
this study that were vaccinated with whole killed cells were
completely protected from fever development and death when
given a high-dose challenge, again correlating with the human
response to vaccination and challenge (1). The guinea pig
aerosol challenge model presented here mimics both the clin-
ical and pathologic changes seen in human acute Q fever and
Q fever pneumonia cases and will provide an accurate and
valuable tool for the study of the general pathogenesis of C.
burnetii infection, for vaccine assessment, and for evaluations
of host immune responses.
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